Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PET tracer (BAY94-9392)
PET tracer · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PET tracer (BAY94-9392) | DRUG | A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds |
Inclusion Criteria: * Males/females \>/= 18 years * Patients with a diagnosis of primary prostate cancer (biopsy proven) and scheduled for radical prostatectomy or patients with prostate tumor recurrence (Patients with advanced tumor disease and a high likelihood to display lymph node metastasis ar...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
The PET tracer (BAY94-9392) is an investigational small molecule imaging agent being developed by Lantheus Holdings, Inc. for use in oncology. It is designed to be used as a positron emission tomography tracer to explore tumor accumulation in patients with cancer. It is currently in Phase 1 clinical development.
The PET tracer (BAY94-9392) is being studied for imaging in patients with neoplasms, specifically to explore tumor accumulation in cancer patients. It is an oncology imaging agent in Phase 1 development and has been evaluated in a single completed clinical trial in the United States.
The PET tracer (BAY94-9392) is being developed by Lantheus Holdings, Inc., which trades on the Nasdaq under the ticker symbol LNTH. Lantheus is the sponsor of the clinical development program for this oncology imaging agent.
The PET tracer (BAY94-9392) is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this agent.
The PET tracer (BAY94-9392) has been studied in one completed Phase 1 trial, NCT01186601, titled Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer. The trial enrolled 30 patients with neoplasms in the United States and has completed.
Yes, the PET tracer is also known as BAY94-9392. BAY94-9392 is an alternative designation for the same investigational oncology imaging agent being developed by Lantheus Holdings, Inc. under the ticker LNTH.